Drugs / PF-06342674
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02045732 | Sep 2014 → Oct 2015 | multiple sclerosis | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT02038764 | Jun 2014 → Sep 2016 | type 1 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01740609 | Nov 2012 → Jun 2014 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06342674 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01740609 ↗ |
| Known as | RN168 | “PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component...” NCT02045732 ↗1“A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of Pf-06342674 (RN168) In Healthy Volunteers” NCT01740609 ↗ |
| Action | Inhibit | “binds to and inhibits the human interleukin-7 receptor” NCT02045732 ↗ |
| Route | Subcutaneous | “Single SC Dose” NCT01740609 ↗ |